TY  - JOUR
AU  - Ibrahim, Mohamed Nabil 
AU  - Elfiky, Abdo Abdellah 
PY  - 2021
TI  - Sofosbuvir May be a Potential Anti-SARS-CoV-2 RdRp Drug
JF  - American Journal of Biochemistry and Biotechnology
VL  - 17
IS  - 2
DO  - 10.3844/ajbbsp.2021.205.207
UR  - https://thescipub.com/abstract/ajbbsp.2021.205.207
AB  - The Coronavirus Diseases 2019 (COVID-19) seriously affecting human health all over the world. More than 107 M people are reported positive for SARS-CoV-2, the virus causing COVID-19 pneumonia, from which +2.3 M died. Nucleotide Inhibitors (NI) have promising results in terms of its efficacy against different viral polymerases, including the Hepatitis C Virus (HCV) Non-Structural Protein 5 B (NS5B) RNA dependent RNA polymerase (RdRp) 1. Thus, the non-structural protein 12 (nsp12) RdRp of the human coronavirus represents an attractive target to develop a possible therapeutic agent. Sofosbuvir proved itself as a potential anti-SARS-CoV-2 RdRp and could inhibit viral replication and infection propagation.